Research programme: protease inhibitors - Virobay

Drug Profile

Research programme: protease inhibitors - Virobay

Alternative Names: VBY-106; VBY-285; VBY-825

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Virobay
  • Class Small molecules
  • Mechanism of Action Cathepsin B inhibitors; Cathepsin inhibitors; Cathepsin S inhibitors; Hepatitis C protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease; Autoimmune disorders; Bone cancer; Neuropathic pain
  • Discontinued Cancer pain; Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Autoimmune-disorders in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Bone-cancer in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top